Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819321 | 0.90 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL12009924 | 0.88 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL8932177 | 0.87 | ADORA2A (0.41) | ADORA2A | |
| SCHEMBL13819327 | 0.86 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL13819325 | 0.86 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL13819328 | 0.86 | ADORA2A (0.34) | ADORA2A | |
| SCHEMBL8932187 | 0.86 | ADORA2A (0.35) | ADORA2A | |
| SCHEMBL13819323 | 0.85 | ADORA2A (0.34) | ADORA2A | |
| SCHEMBL13819324 | 0.84 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL13625892 | 0.83 | GRIN2B (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252767-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.